glp 1 for alcoholism Frontiers GLP-1 receptor agonists are promising

Marketed under the brand name Wegovy, the tablet is authorized for chronic weight management in adults with obesity or who are overweight and also have at least one related health condition

Others are approved for type 2 diabetes and may lead to weight loss as a secondary effect

Preventing the progression of diabetic kidney disease Multimorbidity is common in people with DKD and, therefore, there is an increasing emphasis on comprehensive, holistic medical care to improve overall patient outcomes

JAMA Network Open, 7(1), e2350408

At a $245 monthly price, the new model projected that Medicare would spend nearly $74 billion on GLP-1 drugs over 10 years if coverage expanded, with about $56 billion in downstream health savings thanks to better outcomes associated with diabetes, heart disease, and related complications